PURE Bioscience Reports Fiscal Third Quarter 2013 Results PURE Bioscience, Inc. , creator of the patented silver dihydrogen citrate antimicrobial, reported results for its fiscal third quarter ended April 30, 2013.
June 14, 2013 - Marketwired via Yahoo! Finance
Bruce Downey in FDA news (subscription) We have always believed that our patent challenge settlement related to tamoxifen citrate was pro-consumer and pro-competitive, and this has now been definitively confirmed by the courts,Barr CEO Bruce Downey said.